Scientific exchange · Dr. Yuki Quinn

24 Jul 2026 · Virtual · Dr. Yuki Quinn, Osaka University Hospital · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0053—

Capture insight from this engagement

Location: Osaka University Hospital
Therapeutic area: Oncology
Country: Japan
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Brain-metastasis subgroup data
Sequencing after progression

Scientific content used

PD-L1 testing pathway infographic
irAE management guide

Questions raised

No questions recorded.

Notes

Scientific exchange with thoracic medical oncologist at Osaka University Hospital. Discussed brain-metastasis subgroup data, sequencing after progression.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 5
Strategic relevance: 5
Depth of exchange: 4
Actionability: 5

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0053

Audit history (0)

All create, update and approval events for this record

No audit events in sample data